Article
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Human mutation - 1 Feb 2017
Weren Robbert D A, Mensenkamp Arjen R, Simons Michiel, Eijkelenboom Astrid, Sie Aisha S, Ouchene Hicham, van Asseldonk Monique, Gomez-Garcia Encarna B, Blok Marinus J, de Hullu Joanne A, Nelen Marcel R, Hoischen Alexander, Bulten Johan, Tops Bastiaan B J, Hoogerbrugge Nicoline, Ligtenberg Marjolijn J L
Abstract excerpt
With the recent introduction of Poly(ADP-ribose) polymerase inhibitors, a promising novel therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 or BRCA2 mutations in their tumor. To select patients who may benefit from these treatments, assessment of the mutation status of BRCA1 and BRCA2 in the tumor is required. For reliable evaluation of germline and somatic mutations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.